By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile



172, rue de Charonne

Paris    75545  France
Phone: 33-0-1-40-09-04-11 Fax: 33-0-1-40-09-04-25



Medarex, Inc.  Broad HuMAb-Mouse antibody development agreement and Anti-CTLA-4 cancer vaccine development.

Company News
Epimmune Inc. (EPMN) And IDM S.A. Agree To Combine Businesses10/19/2005 5:13:01 PM
Immuno-Designed Molecules Signs An R&D Agreement On Anti-Cancer Vaccine With The Walter Reed Army Institute of Research10/19/2005 5:12:06 PM
IDM Seeking EUR92 Million In IPO To Fund Programs In Cancer10/19/2005 5:11:43 PM
French Biotech Firm Immuno-Designed Molecules Eyes 99 Millon Euro ($120.7 Million) IPO10/19/2005 5:11:34 PM
Immuno-Designed Molecules Launches A New Phase II/III Trial In Bladder Cancer10/19/2005 5:10:34 PM
IDM S.A. Will Present Phase II Trial Results For Its Melanoma Cancer Vaccine, Uvidem, At American Society of Clinical Oncology - Orlando - On May 15, 200510/19/2005 5:10:30 PM
IDM, Inc. Announces Detailed Phase III Results For Mepact In Osteosarcoma To Be Presented At ASPHO Annual Meeting10/19/2005 5:10:20 PM
Kerry Segal Appointed Vice President, Business Development, At Immuno-Designed Molecules10/19/2005 5:10:15 PM
Epimmune Inc. (EPMN) Stockholders To Vote On Proposed IDM S.A. Business Combination At Annual Meeting Of Stockholders10/19/2005 5:09:24 PM
IDM And Cambridge Laboratories Limited Sign An Exclusive Marketing Agreement For Junovan(TM) (Mepact) In The United Kingdom And Ireland10/19/2005 5:09:19 PM